Over the past decade, the development of EGFR tyrosine kinase inhibitors (TKIs) has revolutionized the therapy of non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR) gene (Zhou et al., 2015; Soria et al., 2018). Here, EGFR is linked to non-small cell lung carcinoma.